Barclays lowered the firm’s price target on Tango Therapeutics to $13 from $18 and keeps an Overweight rating on the shares. The firm noted that Tango discontinued its USP1 inhibitor, TNG348, due to liver toxicity, and the firm is thus removing it from its model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX: